Highlights Imugene Limited

Equities

IMU

AU000000IMU9

Market Closed - Australian S.E. Other stock markets 07:10:13 28/06/2024 BST			5-day change	1st Jan Change
0.057 ^AUD	+5.56%		-3.39%	-48.18%

06-24	Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%	MT
04-16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%	06-24	MT
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	04-16	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	04-15	CI
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	04-15	CI
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	04-04	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-20	MT
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	03-11	CI
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	02-28	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	02-28	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Esken's Southend Airport faces further allegations	01-23	AN
MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene	01-23	MT
Imugene to Open Phase Two Colorectal Cancer Trial in the UK, Australia	12-06	MT
Imugene to Secure European Patent for Cancer Vaccine	12-06	MT
US FDA Transfers Cancer Medication Application to Imugene	28/09/23	MT
Imugene Raises AU$18 Million in Share Purchase Plan	25/09/23	MT
Imugene Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Imugene Secures License for Cell Therapy Program	16/08/23	MT
Precision BioSciences Completes License Deal With Imugene for Cancer Therapy Candidate Azer-Cel	16/08/23	MT
Imugene Limited's CF33 Oncolytic Virus Study to Be Showcase at SITC Annual Meeting	03/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Imugene Limited

Equities

IMU

AU000000IMU9

Highlights

Filters